Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia
Neutrophil gelatinase-associated lipocalin (NGAL) is an acute phase protein that has been reported as a potential marker for pre-dementia stages of Alzheimer's disease (AD). Longitudinal studies for its association with the conversion of mild cognitive impairment to AD is still lacking. This st...
Gespeichert in:
| Veröffentlicht in: | Neurobiology of aging 2021-11, Vol.107, p.1-10 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 10 |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | Neurobiology of aging |
| container_volume | 107 |
| creator | Naudé, Petrus J.W. Ramakers, Inez H.G.B. van der Flier, Wiesje M. Jiskoot, Lize C. Reesink, Fransje E. Claassen, Jurgen A.H.R. Koek, Huiberdina L. Eisel, Ulrich L.M. De Deyn, Peter P. |
| description | Neutrophil gelatinase-associated lipocalin (NGAL) is an acute phase protein that has been reported as a potential marker for pre-dementia stages of Alzheimer's disease (AD). Longitudinal studies for its association with the conversion of mild cognitive impairment to AD is still lacking. This study included n = 268 study participants with subjective cognitive decline (SCD) (n=82), mild cognitive impairment (MCI) (n=98) and AD dementia (n=88) at baseline and two-year follow-up clinical assessments. Serum and cerebrospinal fluid (CSF)NGAL, CSF amyloid beta1-42, total-Tau, and phospho-Tau levels were measured with ELISA analysis. CSF NGAL levels were significantly lower in MCI participants compared to people with SCD at baseline. Lower baseline CSF NGAL levels predicted MCI converters to AD dementia vs. non-converters after 2-years follow-up. A positive correlation between CSF NGAL and amyloid beta1-42 was found particularly in MCI participants at baseline. NGAL in CSF holds potential to be used as a predictive marker for the conversion of MCI to AD dementia and may reflect pathophysiological processes of prodromal AD neuropathology. |
| doi_str_mv | 10.1016/j.neurobiolaging.2021.07.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2559674461</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0197458021002256</els_id><sourcerecordid>2559674461</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-dc74acb6609b6ea191a7a0bda807bf2089335efcda16176618d967cb9c6c6f0d3</originalsourceid><addsrcrecordid>eNqNkc2KFDEUhYMoTjv6CpKF4LioMqmfpAvcNIMzCs24UNchldzqvm0qKZOqhvHBfD7T9CjMztUl3HPuCecj5A1nJWdcvD-UHpYYegxO79DvyopVvGSyZIw_ISvetuuCN518SlaMd7Jo2jW7IC9SOjDGZCPFc3JRN7Voq1asyO-vEJeRam-pgQh9DGlCrx0d3IKW3sEyxzDt0dEdOD3nVYJCpxQM6hksdTgFox16enV3u9m-ow6O4BLVieYfjjr-gJjoECKd90BN8Mf8xuDpEMNIR3Q5N-w8zngEiuOkMY7gZzoHunG_9oAjxLeJWkyQk6mF0xb1S_Js0C7Bq4d5Sb7ffPx2_anYfrn9fL3ZFqZp2FxYIxtteiFY1wvQvONaatZbvWayHyq27uq6hcFYzQWXQvC17YQ0fWeEEQOz9SW5Ot-dYvi5QJrViMmAc9pDWJKq2jYbmkbwLP1wlprcYYowqCliLuBecaZO5NRBPSanTuQUkyqTy_bXD0lLP4L9Z_6LKgtuzoJcLxwRokoGwRuwGMHMygb8v6Q_ON24Xg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2559674461</pqid></control><display><type>article</type><title>Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Naudé, Petrus J.W. ; Ramakers, Inez H.G.B. ; van der Flier, Wiesje M. ; Jiskoot, Lize C. ; Reesink, Fransje E. ; Claassen, Jurgen A.H.R. ; Koek, Huiberdina L. ; Eisel, Ulrich L.M. ; De Deyn, Peter P.</creator><creatorcontrib>Naudé, Petrus J.W. ; Ramakers, Inez H.G.B. ; van der Flier, Wiesje M. ; Jiskoot, Lize C. ; Reesink, Fransje E. ; Claassen, Jurgen A.H.R. ; Koek, Huiberdina L. ; Eisel, Ulrich L.M. ; De Deyn, Peter P.</creatorcontrib><description>Neutrophil gelatinase-associated lipocalin (NGAL) is an acute phase protein that has been reported as a potential marker for pre-dementia stages of Alzheimer's disease (AD). Longitudinal studies for its association with the conversion of mild cognitive impairment to AD is still lacking. This study included n = 268 study participants with subjective cognitive decline (SCD) (n=82), mild cognitive impairment (MCI) (n=98) and AD dementia (n=88) at baseline and two-year follow-up clinical assessments. Serum and cerebrospinal fluid (CSF)NGAL, CSF amyloid beta1-42, total-Tau, and phospho-Tau levels were measured with ELISA analysis. CSF NGAL levels were significantly lower in MCI participants compared to people with SCD at baseline. Lower baseline CSF NGAL levels predicted MCI converters to AD dementia vs. non-converters after 2-years follow-up. A positive correlation between CSF NGAL and amyloid beta1-42 was found particularly in MCI participants at baseline. NGAL in CSF holds potential to be used as a predictive marker for the conversion of MCI to AD dementia and may reflect pathophysiological processes of prodromal AD neuropathology.</description><identifier>ISSN: 0197-4580</identifier><identifier>EISSN: 1558-1497</identifier><identifier>DOI: 10.1016/j.neurobiolaging.2021.07.001</identifier><identifier>PMID: 34365256</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aftercare ; Aged ; Alzheimer Disease - diagnosis ; Amyloid beta ; Amyloid beta-Peptides - cerebrospinal fluid ; Biomarkers - blood ; Biomarkers - cerebrospinal fluid ; Cognitive Dysfunction - diagnosis ; Converters ; Disease Progression ; Female ; Follow-up ; Humans ; Lipocalin 2 ; Lipocalin-2 - blood ; Lipocalin-2 - cerebrospinal fluid ; Male ; Middle Aged ; Neuroinflammation ; Peptide Fragments - cerebrospinal fluid ; Prodromal, Biomarker ; tau Proteins - cerebrospinal fluid</subject><ispartof>Neurobiology of aging, 2021-11, Vol.107, p.1-10</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-dc74acb6609b6ea191a7a0bda807bf2089335efcda16176618d967cb9c6c6f0d3</citedby><cites>FETCH-LOGICAL-c440t-dc74acb6609b6ea191a7a0bda807bf2089335efcda16176618d967cb9c6c6f0d3</cites><orcidid>0000-0002-2228-2964 ; 0000-0003-0520-3475 ; 0000-0001-8766-6224 ; 0000-0003-4178-0384</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.neurobiolaging.2021.07.001$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34365256$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Naudé, Petrus J.W.</creatorcontrib><creatorcontrib>Ramakers, Inez H.G.B.</creatorcontrib><creatorcontrib>van der Flier, Wiesje M.</creatorcontrib><creatorcontrib>Jiskoot, Lize C.</creatorcontrib><creatorcontrib>Reesink, Fransje E.</creatorcontrib><creatorcontrib>Claassen, Jurgen A.H.R.</creatorcontrib><creatorcontrib>Koek, Huiberdina L.</creatorcontrib><creatorcontrib>Eisel, Ulrich L.M.</creatorcontrib><creatorcontrib>De Deyn, Peter P.</creatorcontrib><title>Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia</title><title>Neurobiology of aging</title><addtitle>Neurobiol Aging</addtitle><description>Neutrophil gelatinase-associated lipocalin (NGAL) is an acute phase protein that has been reported as a potential marker for pre-dementia stages of Alzheimer's disease (AD). Longitudinal studies for its association with the conversion of mild cognitive impairment to AD is still lacking. This study included n = 268 study participants with subjective cognitive decline (SCD) (n=82), mild cognitive impairment (MCI) (n=98) and AD dementia (n=88) at baseline and two-year follow-up clinical assessments. Serum and cerebrospinal fluid (CSF)NGAL, CSF amyloid beta1-42, total-Tau, and phospho-Tau levels were measured with ELISA analysis. CSF NGAL levels were significantly lower in MCI participants compared to people with SCD at baseline. Lower baseline CSF NGAL levels predicted MCI converters to AD dementia vs. non-converters after 2-years follow-up. A positive correlation between CSF NGAL and amyloid beta1-42 was found particularly in MCI participants at baseline. NGAL in CSF holds potential to be used as a predictive marker for the conversion of MCI to AD dementia and may reflect pathophysiological processes of prodromal AD neuropathology.</description><subject>Aftercare</subject><subject>Aged</subject><subject>Alzheimer Disease - diagnosis</subject><subject>Amyloid beta</subject><subject>Amyloid beta-Peptides - cerebrospinal fluid</subject><subject>Biomarkers - blood</subject><subject>Biomarkers - cerebrospinal fluid</subject><subject>Cognitive Dysfunction - diagnosis</subject><subject>Converters</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Follow-up</subject><subject>Humans</subject><subject>Lipocalin 2</subject><subject>Lipocalin-2 - blood</subject><subject>Lipocalin-2 - cerebrospinal fluid</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neuroinflammation</subject><subject>Peptide Fragments - cerebrospinal fluid</subject><subject>Prodromal, Biomarker</subject><subject>tau Proteins - cerebrospinal fluid</subject><issn>0197-4580</issn><issn>1558-1497</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc2KFDEUhYMoTjv6CpKF4LioMqmfpAvcNIMzCs24UNchldzqvm0qKZOqhvHBfD7T9CjMztUl3HPuCecj5A1nJWdcvD-UHpYYegxO79DvyopVvGSyZIw_ISvetuuCN518SlaMd7Jo2jW7IC9SOjDGZCPFc3JRN7Voq1asyO-vEJeRam-pgQh9DGlCrx0d3IKW3sEyxzDt0dEdOD3nVYJCpxQM6hksdTgFox16enV3u9m-ow6O4BLVieYfjjr-gJjoECKd90BN8Mf8xuDpEMNIR3Q5N-w8zngEiuOkMY7gZzoHunG_9oAjxLeJWkyQk6mF0xb1S_Js0C7Bq4d5Sb7ffPx2_anYfrn9fL3ZFqZp2FxYIxtteiFY1wvQvONaatZbvWayHyq27uq6hcFYzQWXQvC17YQ0fWeEEQOz9SW5Ot-dYvi5QJrViMmAc9pDWJKq2jYbmkbwLP1wlprcYYowqCliLuBecaZO5NRBPSanTuQUkyqTy_bXD0lLP4L9Z_6LKgtuzoJcLxwRokoGwRuwGMHMygb8v6Q_ON24Xg</recordid><startdate>202111</startdate><enddate>202111</enddate><creator>Naudé, Petrus J.W.</creator><creator>Ramakers, Inez H.G.B.</creator><creator>van der Flier, Wiesje M.</creator><creator>Jiskoot, Lize C.</creator><creator>Reesink, Fransje E.</creator><creator>Claassen, Jurgen A.H.R.</creator><creator>Koek, Huiberdina L.</creator><creator>Eisel, Ulrich L.M.</creator><creator>De Deyn, Peter P.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2228-2964</orcidid><orcidid>https://orcid.org/0000-0003-0520-3475</orcidid><orcidid>https://orcid.org/0000-0001-8766-6224</orcidid><orcidid>https://orcid.org/0000-0003-4178-0384</orcidid></search><sort><creationdate>202111</creationdate><title>Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia</title><author>Naudé, Petrus J.W. ; Ramakers, Inez H.G.B. ; van der Flier, Wiesje M. ; Jiskoot, Lize C. ; Reesink, Fransje E. ; Claassen, Jurgen A.H.R. ; Koek, Huiberdina L. ; Eisel, Ulrich L.M. ; De Deyn, Peter P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-dc74acb6609b6ea191a7a0bda807bf2089335efcda16176618d967cb9c6c6f0d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aftercare</topic><topic>Aged</topic><topic>Alzheimer Disease - diagnosis</topic><topic>Amyloid beta</topic><topic>Amyloid beta-Peptides - cerebrospinal fluid</topic><topic>Biomarkers - blood</topic><topic>Biomarkers - cerebrospinal fluid</topic><topic>Cognitive Dysfunction - diagnosis</topic><topic>Converters</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Follow-up</topic><topic>Humans</topic><topic>Lipocalin 2</topic><topic>Lipocalin-2 - blood</topic><topic>Lipocalin-2 - cerebrospinal fluid</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neuroinflammation</topic><topic>Peptide Fragments - cerebrospinal fluid</topic><topic>Prodromal, Biomarker</topic><topic>tau Proteins - cerebrospinal fluid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Naudé, Petrus J.W.</creatorcontrib><creatorcontrib>Ramakers, Inez H.G.B.</creatorcontrib><creatorcontrib>van der Flier, Wiesje M.</creatorcontrib><creatorcontrib>Jiskoot, Lize C.</creatorcontrib><creatorcontrib>Reesink, Fransje E.</creatorcontrib><creatorcontrib>Claassen, Jurgen A.H.R.</creatorcontrib><creatorcontrib>Koek, Huiberdina L.</creatorcontrib><creatorcontrib>Eisel, Ulrich L.M.</creatorcontrib><creatorcontrib>De Deyn, Peter P.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurobiology of aging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Naudé, Petrus J.W.</au><au>Ramakers, Inez H.G.B.</au><au>van der Flier, Wiesje M.</au><au>Jiskoot, Lize C.</au><au>Reesink, Fransje E.</au><au>Claassen, Jurgen A.H.R.</au><au>Koek, Huiberdina L.</au><au>Eisel, Ulrich L.M.</au><au>De Deyn, Peter P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia</atitle><jtitle>Neurobiology of aging</jtitle><addtitle>Neurobiol Aging</addtitle><date>2021-11</date><risdate>2021</risdate><volume>107</volume><spage>1</spage><epage>10</epage><pages>1-10</pages><issn>0197-4580</issn><eissn>1558-1497</eissn><abstract>Neutrophil gelatinase-associated lipocalin (NGAL) is an acute phase protein that has been reported as a potential marker for pre-dementia stages of Alzheimer's disease (AD). Longitudinal studies for its association with the conversion of mild cognitive impairment to AD is still lacking. This study included n = 268 study participants with subjective cognitive decline (SCD) (n=82), mild cognitive impairment (MCI) (n=98) and AD dementia (n=88) at baseline and two-year follow-up clinical assessments. Serum and cerebrospinal fluid (CSF)NGAL, CSF amyloid beta1-42, total-Tau, and phospho-Tau levels were measured with ELISA analysis. CSF NGAL levels were significantly lower in MCI participants compared to people with SCD at baseline. Lower baseline CSF NGAL levels predicted MCI converters to AD dementia vs. non-converters after 2-years follow-up. A positive correlation between CSF NGAL and amyloid beta1-42 was found particularly in MCI participants at baseline. NGAL in CSF holds potential to be used as a predictive marker for the conversion of MCI to AD dementia and may reflect pathophysiological processes of prodromal AD neuropathology.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34365256</pmid><doi>10.1016/j.neurobiolaging.2021.07.001</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-2228-2964</orcidid><orcidid>https://orcid.org/0000-0003-0520-3475</orcidid><orcidid>https://orcid.org/0000-0001-8766-6224</orcidid><orcidid>https://orcid.org/0000-0003-4178-0384</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0197-4580 |
| ispartof | Neurobiology of aging, 2021-11, Vol.107, p.1-10 |
| issn | 0197-4580 1558-1497 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2559674461 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Aftercare Aged Alzheimer Disease - diagnosis Amyloid beta Amyloid beta-Peptides - cerebrospinal fluid Biomarkers - blood Biomarkers - cerebrospinal fluid Cognitive Dysfunction - diagnosis Converters Disease Progression Female Follow-up Humans Lipocalin 2 Lipocalin-2 - blood Lipocalin-2 - cerebrospinal fluid Male Middle Aged Neuroinflammation Peptide Fragments - cerebrospinal fluid Prodromal, Biomarker tau Proteins - cerebrospinal fluid |
| title | Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T15%3A17%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20and%20cerebrospinal%20fluid%20Neutrophil%20gelatinase-associated%20lipocalin%20(NGAL)%20levels%20as%20biomarkers%20for%20the%20conversion%20from%20mild%20cognitive%20impairment%20to%20Alzheimer's%20disease%20dementia&rft.jtitle=Neurobiology%20of%20aging&rft.au=Naud%C3%A9,%20Petrus%20J.W.&rft.date=2021-11&rft.volume=107&rft.spage=1&rft.epage=10&rft.pages=1-10&rft.issn=0197-4580&rft.eissn=1558-1497&rft_id=info:doi/10.1016/j.neurobiolaging.2021.07.001&rft_dat=%3Cproquest_cross%3E2559674461%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2559674461&rft_id=info:pmid/34365256&rft_els_id=S0197458021002256&rfr_iscdi=true |